ESMO 2020 | CheckMate 214 trial update

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CheckMate 214 clinical trial (NCT02231749), involving nivolumab + ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC), in a 4-year follow-up and subgroup analysis of patients without nephrectomy. After 4 years follow-up, overall survival (OS) and objective response rate (ORR) benefits were maintained with nivolumab + ipilimumab vs sunitinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).